Among other relevant findings, this study, which was conducted in different tumor types, also demonstrated that further variables related to T cell biology, such as T-helper type 1 gene expression (interferon-gamma, CD27, CXCR3, CD45RO, GZMB and CD8A), CTLA4 expression, and the absence of fractalkine (CX3CL1), in baseline tumor specimens can significantly predict benefit after ICI. The gene discussed is CTLA4; the disease is neoplasm.